البحث عن طبيب

Jeffrey E. Johnson, M.D.

  1. Surgical Oncologist

المنشورات

  1. Steadman JA, Hoskin TL, Klassen C, Boughey JC, Degnim AC, Piltin MA, Mrdutt MM, Johnson JE, Hieken TJ. Assessment of the effect of the American Society of Breast Surgery guidelines on contralateral prophylactic mastectomy rates for unilateral breast cancer. Surgery. 2024 Mar; 175 (3):677-686 Epub 2023 Oct 19
    View PubMed
  2. Johnson JE, Strassle PD, de Oliveira GC, Agala CB, Spanheimer P, Gallagher K, Ollila D, Muss H, Downs-Canner S. Suboptimal therapy following breast conserving surgery in triple-negative and HER2-positive breast cancer patients. Breast Cancer Res Treat. 2021 Sep; 189 (2):509-520 Epub 2021 June 26
    View PubMed
  3. Crystal JS, Rand J, Johnson J, Kim S, Basho R, Amersi F, Giuliano AE, Chung A. Adjuvant endocrine therapy is associated with improved overall survival in elderly hormone receptor-positive breast cancer patients. Breast Cancer Res Treat. 2020 Nov; 184 (1):63-74 Epub 2020 Aug 09
    View PubMed
  4. Bloom MB, Johnson J, Volod O, Lee EY, White T, Margulies DR. Improved prediction of HIT in the SICU using an improved model of the Warkentin 4-T system: 3-T. Am J Surg. 2020 Jan; 219 (1):54-57 Epub 2019 July 29
    View PubMed
  5. Manguso N, Gangi A, Johnson J, Harit A, Nissen N, Jamil L, Lo S, Wachsman A, Hendifar A, Amersi F. The role of pre-operative imaging and double balloon enteroscopy in the surgical management of small bowel neuroendocrine tumors: Is it necessary? J Surg Oncol. 2018 Feb; 117 (2):207-212 Epub 2017 Sept 20
    View PubMed
  6. Manguso N, Johnson J, Harit A, Nissen N, Mirocha J, Hendifar A, Amersi F. Prognostic Factors Associated with Outcomes in Small Bowel Neuroendocrine Tumors. Am Surg. 2017 Oct 1; 83 (10):1174-1178
    View PubMed
  7. Marotta M, Onodera T, Johnson J, Budd GT, Watanabe T, Cui X, Giuliano AE, Niida A, Tanaka H. Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumors. Sci Rep. 2017 Feb 17; 7:41921
    View PubMed
  8. Johnson J, Choi M, Dadmanesh F, Han B, Qu Y, Yu-Rice Y, Zhang X, Bagaria S, Taylor C, Giuliano AE, Amersi F, Cui X. FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort. Oncotarget. 2016 Nov 15; 7(46):75729-75738.
    View PubMed
  9. Yu-Rice Y, Jin Y, Han B, Qu Y, Johnson J, Watanabe T, Cheng L, Deng N, Tanaka H, Gao B, Liu Z, Sun Z, Bose S, Giuliano AE, Cui X. FOXC1 is involved in ERalpha silencing by counteracting GATA3 binding and is implicated in endocrine resistance. Oncogene. 2016 Oct 13; 35 (41):5400-5411 Epub 2016 Apr 04
    View PubMed
  10. Qu Y, Zhou B, Yang W, Han B, Yu-Rice Y, Gao B, Johnson J, Svendsen CN, Freeman MR, Giuliano AE, Sareen D, Cui X. Transcriptome and proteome characterization of surface ectoderm cells differentiated from human iPSCs. Sci Rep. 2016 Aug 23; 6:32007
    View PubMed
  11. Han B, Qu Y, Yu-Rice Y, Johnson J, Cui X. FOXC1-induced Gli2 activation: A non-canonical pathway contributing to stemness and anti-Hedgehog resistance in basal-like breast cancer. Mol Cell Oncol. 2016 May; 3 (3):e1131668 Epub 2016 Jan 11
    View PubMed
  12. Han B, Qu Y, Jin Y, Yu Y, Deng N, Wawrowsky K, Zhang X, Li N, Bose S, Wang Q, Sakkiah S, Abrol R, Jensen TW, Berman BP, Tanaka H, Johnson J, Gao B, Hao J, Liu Z, Buttyan R, Ray PS, Hung MC, Giuliano AE, Cui X. FOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-like Breast Cancer. Cell Rep. 2015 Nov 3; 13 (5):1046-58
    View PubMed
  13. Czuczman MS, Porcu P, Johnson J, Niedzwiecki D, Kelly M, Hsi ED, Cook JR, Canellos G, Cheson BD, Cancer and Leukemia Group B. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lymphoma. 2007 Jan; 48 (1):97-103
    View PubMed